Table 2.

Thickness of central macula and parafoveal inner retinal layer in each group.

	Bevacizumab group	PRP group	P value*
CMT
Baseline	269.7 ± 22.6	268.8 ± 31.2	0.881
1 month	265.1 ± 20.4	276.1 ± 26.5	0.050
3 months	267.9 ± 21.4	281.7 ± 32.6	0.035
6 months	263.9 ± 21.4	287.3 ± 39.8	0.002
P value†	0.073	0.035
RNFL
Baseline	25.8 ± 4.0	27.0 ± 6.5	0.335
1 month	24.5 ± 3.7	29.5 ± 6.6	< 0.001
3 months	24.4 ± 3.4	31.0 ± 8.6	0.009
6 months	24.4 ± 3.5	29.7 ± 7.1	0.005
P value	< 0.001	0.087
GCL
Baseline	49.1 ± 6.4	47.5 ± 7.8	0.330
1 month	48.2 ± 6.9	49.7 ± 7.5	0.390
3 months	48.2 ± 6.8	50.3 ± 8.5	0.201
6 months	47.8 ± 6.4	50.7 ± 8.5	0.102
P value	0.013	0.005
IPL
Baseline	40.4 ± 3.9	39.9 ± 5.6	0.665
1 month	39.5 ± 4.3	41.6 ± 5.1	0.063
3 months	39.6 ± 4.1	41.5 ± 5.3	0.087
6 months	39.9 ± 4.2	41.5 ± 5.3	0.149
P value	0.017	0.003

Values in boldface (P < 0.05) are statistically significant.

All values are expressed as the mean ± SD (μm).

CMT central macular thickness, RNFL retinal nerve fiber layer, GCL ganglion cell layer, IPL inner plexiform layer.

*Calculated for ANCOVA after adjusting for age.

^†Calculated for repeated-measures ANOVA.